HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Hemogenyx Pharmaceuticals is set to launch its Phase I clinical trial for HEMO-CAR-T, a promising new therapy targeting relapsed/refractory acute myeloid leukemia in adults, marking a significant milestone for the company. The trial, designed to assess safety and efficacy, will commence following anticipated approval and site initiation in November. This development reflects Hemogenyx’s commitment to offering innovative solutions for patients with limited treatment options.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
